Tiludronate disodium

Tiludronate disodium
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318873

CAS#: 149845-07-8 (sodium)

Description: Tiludronate is a bisphosphonate used for treatment of Paget's disease of bone (osteitis deformans) in human medicine. In veterinary medicine, tiludronic acid is used to treat navicular disease and bone spavin in horses. Its trade names are Tildren and Equidronate. It is approved for treatment of navicular disease and distal tarsal osteoarthritis in Europe, and was approved for treatment of navicular disease in the United States in 2014. Tiludronate is a non-nitrogenous bisphosphonate that inhibits osteoclasts, the primary cell responsible for the breakdown of bone required for bone remodeling.

Chemical Structure

Tiludronate disodium

CAS# 149845-07-8 (sodium)

Handing Instruction

Theoretical Analysis

MedKoo Cat#: 318873
Name: Tiludronate disodium
CAS#: 149845-07-8 (sodium)
Chemical Formula: C7H7ClNa2O6P2S
Exact Mass:
Molecular Weight: 362.56406
Elemental Analysis: C, 23.19; H, 1.95; Cl, 9.78; Na, 12.68; O, 26.48; P, 17.09; S, 8.84

Size	Price	Shipping out time
50mg	USD 450	2 Weeks
100mg	USD 750	2 Weeks
Inquire bulk and customized quantity Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Pricing updated 2021-03-07. Prices are subject to change without notice.

Tiludronate disodium, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide). Shipping fee: from $30.00 (USA); from $45.00 (Canada); from $70.00 (international).

Related CAS #: 114084-78-5 (free acid) 149845-07-8 (sodium) 138926-19-9 (sodium hydrate)

Synonym: Tiludronate disodium; Tiludronic acid. trade name Skelid; Tildren and Equidronate.

IUPAC/Chemical Name: [(4-chlorophenyl)sulfanyl-[hydroxy(oxido)phosphoryl]methyl]-hydroxyphosphinate disodium

InChi Key: SKUHWSDHMJMHIW-UHFFFAOYSA-L

InChi Code: InChI=1S/C7H9ClO6P2S.2Na/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14;;/h1-4,7H,(H2,9,10,11)(H2,12,13,14);;/q;2*+1/p-2

SMILES Code: O=P(O)(C(SC1=CC=C(Cl)C=C1)P([O-])(O)=O)[O-].[Na+].[Na+]

Appearance:

Solid powder

Purity:

>98% (or refer to the Certificate of Analysis)

Shipping Condition:

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:

Soluble in DMSO, not in water

Shelf Life:

>2 years if stored properly

Drug Formulation:

This drug may be formulated in DMSO

Stock Solution Storage:

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

2934.99.9001

Handling Instructions:

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 362.56406 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Reconstitution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Gourlay J. Licence variations regarding tiludronate disodium. Vet Rec. 2015 Oct 24;177(16):423-4. doi: 10.1136/vr.h5621. PubMed PMID: 26494897.

2: Hunter BG, Duesterdieck-Zellmer KF, Larson MK. Tiludronate concentrations and cytologic findings in synovial fluid after intravenous regional limb perfusion with tiludronate in horses. PeerJ. 2015 Apr 28;3:e889. doi: 10.7717/peerj.889. eCollection 2015. PubMed PMID: 25945303; PubMed Central PMCID: PMC4419440.

3: Duesterdieck-Zellmer KF, Moneta L, Ott JF, Larson MK, Gorman EM, Hunter B, Löhr CV, Payton ME, Morré JT, Maier CS. Effects of low and high dose intraarticular tiludronate on synovial fluid and clinical variables in healthy horses-a preliminary investigation. PeerJ. 2014 Sep 4;2:e534. doi: 10.7717/peerj.534. eCollection 2014. PubMed PMID: 25237596; PubMed Central PMCID: PMC4157236.

4: Popot MA, Garcia P, Hubert C, Bolopion A, Bailly-Chouriberry L, Bonnaire Y, Thibaud D, Guyonnet J. HPLC/ESI-MS(n) method for non-amino bisphosphonates: application to the detection of tiludronate in equine plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2014 May 1;958:108-16. doi: 10.1016/j.jchromb.2014.03.018. Epub 2014 Mar 26. PubMed PMID: 24732148.

5: Pascaud P, Gras P, Coppel Y, Rey C, Sarda S. Interaction between a bisphosphonate, tiludronate, and biomimetic nanocrystalline apatites. Langmuir. 2013 Feb 19;29(7):2224-32. doi: 10.1021/la3046548. Epub 2013 Feb 4. PubMed PMID: 23317459.

6: Duesterdieck-Zellmer KF, Driscoll N, Ott JF. Concentration-dependent effects of tiludronate on equine articular cartilage explants incubated with and without interleukin-1β. Am J Vet Res. 2012 Oct;73(10):1530-9. PubMed PMID: 23013178.

7: Pascaud P, Bareille R, Bourget C, Amédée J, Rey C, Sarda S. Interaction between a bisphosphonate, tiludronate and nanocrystalline apatite: in vitro viability and proliferation of HOP and HBMSC cells. Biomed Mater. 2012 Oct;7(5):054108. doi: 10.1088/1748-6041/7/5/054108. Epub 2012 Sep 12. PubMed PMID: 22972389.

8: Delguste C, Doucet M, Gabriel A, Guyonnet J, Lepage OM, Amory H. Assessment of a bone biopsy technique for measuring tiludronate in horses: a preliminary study. Can J Vet Res. 2011 Apr;75(2):128-33. PubMed PMID: 21731184; PubMed Central PMCID: PMC3062923.

9: Moreau M, Rialland P, Pelletier JP, Martel-Pelletier J, Lajeunesse D, Boileau C, Caron J, Frank D, Lussier B, del Castillo JR, Beauchamp G, Gauvin D, Bertaim T, Thibaud D, Troncy E. Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. Arthritis Res Ther. 2011 Jun 21;13(3):R98. doi: 10.1186/ar3373. PubMed PMID: 21693018; PubMed Central PMCID: PMC3218913.

10: Gough MR, Thibaud D, Smith RK. Tiludronate infusion in the treatment of bone spavin: a double blind placebo-controlled trial. Equine Vet J. 2010 Jul;42(5):381-7. doi: 10.1111/j.2042-3306.2010.00120.x. PubMed PMID: 20636772.

11: Deshmukh DD, Nagilla R, Ravis WR, Betageri GV. Effect of dodecylmaltoside (DDM) on uptake of BCS III compounds, tiludronate and cromolyn, in Caco-2 cells and rat intestine model. Drug Deliv. 2010 Apr;17(3):145-51. doi: 10.3109/10717541003604882. PubMed PMID: 20136582.

12: Delguste C, Amory H, Guyonnet J, Thibaud D, Garnero P, Detilleux J, Lepage OM, Doucet M. Comparative pharmacokinetics of two intravenous administration regimens of tiludronate in healthy adult horses and effects on the bone resorption marker CTX-1. J Vet Pharmacol Ther. 2008 Apr;31(2):108-16. doi: 10.1111/j.1365-2885.2007.00936.x. PubMed PMID: 18307502.

13: Delguste C, Amory H, Doucet M, Piccot-Crézollet C, Thibaud D, Garnero P, Detilleux J, Lepage OM. Pharmacological effects of tiludronate in horses after long-term immobilization. Bone. 2007 Sep;41(3):414-21. Epub 2007 May 23. PubMed PMID: 17604709.

14: Peris P, Alvarez L, Vidal S, Martínez MA, Monegal A, Guañabens N. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy. Clin Exp Rheumatol. 2007 Mar-Apr;25(2):206-10. PubMed PMID: 17543143.

15: Coudry V, Thibaud D, Riccio B, Audigié F, Didierlaurent D, Denoix JM. Efficacy of tiludronate in the treatment of horses with signs of pain associated with osteoarthritic lesions of the thoracolumbar vertebral column. Am J Vet Res. 2007 Mar;68(3):329-37. PubMed PMID: 17331024.

16: Yoshida M, Tokuda H, Ishisaki A, Kanno Y, Harada A, Shimuzu K, Kozawa O. Tiludronate inhibits prostaglandin F2alpha-induced vascular endothelial growth factor synthesis in osteoblasts. Mol Cell Endocrinol. 2005 May 31;236(1-2):59-66. Epub 2005 Apr 7. PubMed PMID: 15922088.

17: Denoix JM, Thibaud D, Riccio B. Tiludronate as a new therapeutic agent in the treatment of navicular disease: a double-blind placebo-controlled clinical trial. Equine Vet J. 2003 Jun;35(4):407-13. PubMed PMID: 12880010.

18: Reginster JY, Christiansen C, Roux C, Fechtenbaum J, Rouillon A, Tou KP. Intermittent cyclic tiludronate in the treatment of osteoporosis. Osteoporos Int. 2001;12(3):169-77. PubMed PMID: 11315234.

19: Morales-Piga A. Tiludronate. A new treatment for an old ailment: Paget's disease of bone. Expert Opin Pharmacother. 1999 Nov;1(1):157-70. Review. PubMed PMID: 11249559.

20: Rohanizadeh R, LeGeros RZ, Bohic S, Pilet P, Barbier A, Daculsi G. Ultrastructural properties of bone mineral of control and tiludronate-treated osteoporotic rat. Calcif Tissue Int. 2000 Oct;67(4):330-6. PubMed PMID: 11000348.

Your view history

50mg / USD 450

Additional Information

Related CAS#
CAS#149845-07-8 (Tiludronate disodium salt)
CAS#89987-06-4 (Tiludronate free acid)